ARTISTRY studies of Nemvaleukin alfa, a novel engineered selective IL-2 fusion protein, revealed that it stimulates NK cells and CD8+ T cells and potentially switches “cold” tumour phenotypes to “hot”. Here, CD8A is linked to neoplasm.